A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
|
| Abstract |
Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was manageable. There is a trend suggesting that hENT1 expression influences response to cytarabine, but not sufficient to support it as a biomarker for guiding treatment. Further, we conclude that the activity of elacytarabine is not significantly predicted by the hENT1 expression level.
|
|---|---|
| Authors | David Rizzieri, Norbert Vey, Xavier Thomas, Françoise Huguet-Rigal, Richard F Schlenk, Jürgen Krauter, Thomas Kindler, Bjørn Tore Gjertsen, Igor Wolfgang Blau, Tove Flem Jacobsen, Malin Johansen, Trygve Bergeland, Athos Gianella-Borradori, Utz Krug |
| Journal | Leukemia & lymphoma (Leuk Lymphoma) Vol. 55 Issue 9 Pg. 2114-9 (Sep 2014) ISSN: 1029-2403 [Electronic] United States |
| PMID | 24255981 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!